complanadine B: isolated from Lycopodium complanatum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Lycopodium | genus | A plant genus of the family LYCOPODIACEAE. Members contain ALKALOIDS. Lycopodium oil is obtained from L. clavatum.[MeSH] | Lycopodiaceae | The club-moss plant family of the order Lycopodiales, class Lycopodiopsida, division Lycopodiophyta, subkingdom TRACHEOPHYTA. The common name of clubmoss applies to several genera of this family. Despite the name this is not one of the true mosses (BRYOPSIDA ).[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 11488838 |
| CHEMBL ID | 1644380 |
| MeSH ID | M0586911 |
| Synonym |
|---|
| CHEMBL1644380 |
| complanadine b |
| (1r,9r,10r,16r)-16-methyl-5-[(1r,9s,10r,16r)-16-methyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-8-one |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID552427 | Induction of neurotrophic factor mRNA expression in human 1321N1 cells at 100 uM by RT-PCR analysis relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2 | Lyconadins D and E, and complanadine E, new Lycopodium alkaloids from Lycopodium complanatum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||